home
Number
Title
Author
Date
137
Pharmaceutical firm HLB plans to move to main bourse from KOSDAQ
admin
2023.09.25
136
HLB on a quest for next-generation target cancer therapy CAR-T: CEO interview
admin
2023.09.11
135
HLB "Published in the 'Lancet' results of the Phase 3 clinical trial of riboceranib"
admin
2023.07.26
134
FDA Accepts NDA for Rivoceranib Plus Camrelizumab in Unresectable HCC
admin
2023.07.18
133
HLB To Acquire PANAGENE To Strengthen Cancer Diagnosis Business Portfolio
admin
2023.06.22
132
Elevar Therapeutics to Participate in ASCO 2023 and BIO 2023; New Jersey-based Company Secures State License as It Builds Toward
admin
2023.06.07
131
FDA Approval Sought for Frontline Camrelizumab Plus Rivoceranib in uHCC
admin
2023.05.23
130
Elevar submits new drug application for uHCC combo therapy
admin
2023.05.23
129
HLB seeks approval for liver cancer drug with US FDA
admin
2023.05.23
128
HLB ends split-off of ship business to focus on bio sector
admin
2023.04.21